Neoadjuvant chemotherapy with weekly docetaxel followed from concomitant docetaxel-RT in patients with high risk locally advanced prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 25 May 2012
At a glance
- Drugs Docetaxel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Acronyms DOCRTPC
- 10 Jun 2017 Biomarkers information updated
- 25 May 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
- 31 Jul 2011 New trial record